Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

PDE5 inhibition mitigates heart failure in hyperlipidemia

Huang, Wuqing LU orcid ; Yang, Xi LU ; Zhang, Naiqi LU ; Chen, Keyuan ; Xiao, Jun LU ; Qiu, Zhihuang ; You, Sujun ; Gao, Ziting ; Ji, Jianguang LU orcid and Chen, Liangwan (2024) In Biomedicine and Pharmacotherapy 175.
Abstract

PDE5 inhibitors was reported to play a protective role in both regulating lipid metabolism and reducing heart failure (HF). This study aimed to clarify the effectiveness of PDE5 inhibitors against hyperlipidemia-related HF by combining evidence from population-based study and animal models. The nationwide cohort study found that post-diagnostic use of PDE5 inhibitors was associated with a significantly lower risk of HF compared with patients who used alprostadil, especially among individuals with hyperlipidemia (adjusted HR = 0.56, 95% CI = 0.40–0.78). In animal models, sildenafil significantly recovered the cardiac structure and function induced by AAB surgery, as well as reversed liver dysfunction and ameliorated hyperlipidemia... (More)

PDE5 inhibitors was reported to play a protective role in both regulating lipid metabolism and reducing heart failure (HF). This study aimed to clarify the effectiveness of PDE5 inhibitors against hyperlipidemia-related HF by combining evidence from population-based study and animal models. The nationwide cohort study found that post-diagnostic use of PDE5 inhibitors was associated with a significantly lower risk of HF compared with patients who used alprostadil, especially among individuals with hyperlipidemia (adjusted HR = 0.56, 95% CI = 0.40–0.78). In animal models, sildenafil significantly recovered the cardiac structure and function induced by AAB surgery, as well as reversed liver dysfunction and ameliorated hyperlipidemia induced by HFD via reducing the level of ALT, AST and serum lipids. Lipidomic analysis identified four lipid metabolites involved in sildenafil administration, including FA 16:3, LPC O-18:1, DG24:0_18:0 and SE28:1/20:4. This study revealed the protective effect of PDE5 inhibitors against HF in hyperlipidemia, indicating the potential of being repurposed as an adjuvant for HF prevention in patients with hyperlipidemia if these findings can be further confirmed in clinical trials.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Heart failure, Hyperlipidemia, PDE5 inhibitors
in
Biomedicine and Pharmacotherapy
volume
175
article number
116710
publisher
Elsevier
external identifiers
  • scopus:85192201726
  • pmid:38713942
ISSN
0753-3322
DOI
10.1016/j.biopha.2024.116710
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2024 The Authors
id
55e86694-a779-41bd-8fd7-4908d5a4cfb6
date added to LUP
2024-05-12 12:15:25
date last changed
2024-06-23 15:39:21
@article{55e86694-a779-41bd-8fd7-4908d5a4cfb6,
  abstract     = {{<p>PDE5 inhibitors was reported to play a protective role in both regulating lipid metabolism and reducing heart failure (HF). This study aimed to clarify the effectiveness of PDE5 inhibitors against hyperlipidemia-related HF by combining evidence from population-based study and animal models. The nationwide cohort study found that post-diagnostic use of PDE5 inhibitors was associated with a significantly lower risk of HF compared with patients who used alprostadil, especially among individuals with hyperlipidemia (adjusted HR = 0.56, 95% CI = 0.40–0.78). In animal models, sildenafil significantly recovered the cardiac structure and function induced by AAB surgery, as well as reversed liver dysfunction and ameliorated hyperlipidemia induced by HFD via reducing the level of ALT, AST and serum lipids. Lipidomic analysis identified four lipid metabolites involved in sildenafil administration, including FA 16:3, LPC O-18:1, DG24:0_18:0 and SE28:1/20:4. This study revealed the protective effect of PDE5 inhibitors against HF in hyperlipidemia, indicating the potential of being repurposed as an adjuvant for HF prevention in patients with hyperlipidemia if these findings can be further confirmed in clinical trials.</p>}},
  author       = {{Huang, Wuqing and Yang, Xi and Zhang, Naiqi and Chen, Keyuan and Xiao, Jun and Qiu, Zhihuang and You, Sujun and Gao, Ziting and Ji, Jianguang and Chen, Liangwan}},
  issn         = {{0753-3322}},
  keywords     = {{Heart failure; Hyperlipidemia; PDE5 inhibitors}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Biomedicine and Pharmacotherapy}},
  title        = {{PDE5 inhibition mitigates heart failure in hyperlipidemia}},
  url          = {{http://dx.doi.org/10.1016/j.biopha.2024.116710}},
  doi          = {{10.1016/j.biopha.2024.116710}},
  volume       = {{175}},
  year         = {{2024}},
}